-
Genomic analysis of an aggressive hepatic leiomyosarcoma case following treatment for hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2024-03-09 Yuto Numata, Noriyuki Akutsu, Masashi Idogawa, Kohei Wagatsuma, Yasunao Numata, Keisuike Ishigami, Tomoya Nakamura, Takehiro Hirano, Yujiro Kawakami, Yoshiharu Masaki, Ayako Murota, Shigeru Sasaki, Hiroshi Nakase
A 70‐year‐old man undergoing treatment for immunoglobulin G4‐related disease developed a liver mass on computed tomography during routine imaging examination. The tumor was located in the hepatic S1/4 region, was 38 mm in size, and showed arterial enhancement on dynamic contrast‐enhanced computed tomography. We performed a liver biopsy and diagnosed moderately differentiated hepatocellular carcinoma
-
Natural history and clinical features of hepatitis C virus infection during childhood: A nationwide, observational survey in Japan Hepatol. Res. (IF 4.2) Pub Date : 2024-03-09 Satoshi Nakano, Mitsuyoshi Suzuki, Reiko Hatori, Tatsuki Mizuochi, Yuri Etani, Hitoshi Tajiri
-
Optimal treatment strategy and prognostic analysis of salvage liver transplantation for patients with early hepatocellular carcinoma recurrence after hepatectomy Hepatol. Res. (IF 4.2) Pub Date : 2024-03-07 Hao‐Chien Hung, Yin Lai, Jin‐Chiao Lee, Yu‐Chao Wang, Chih‐Hsien Cheng, Tsung‐Han Wu, Ting‐Jung Wu, Hong‐Shiue Chou, Kun‐Ming Chan, Wei‐Chen Lee, Chen‐Fang Lee
AimWe aimed to investigate the prognostic factors for salvage liver transplant in patients with early hepatocellular carcinoma recurrence after hepatectomy.MethodsThis retrospective analysis included 53 patients who underwent salvage living‐donor liver transplantation between January 2007 and January 2018. There were 24 and 29 patients in the early (recurrence ≤24 months after primary liver resection)
-
Issue Information Hepatol. Res. (IF 4.2) Pub Date : 2024-03-02
No abstract is available for this article.
-
High expression of autotaxin is associated with poor recurrence‐free survival in cholangiocarcinoma Hepatol. Res. (IF 4.2) Pub Date : 2024-03-02 Xuefeng Li, Yukinori Koyama, Kojiro Taura, Takahiro Nishio, Tomoaki Yoh, Hiroto Nishino, Yusuke Uemoto, Yusuke Kimura, Daichi Nakamura, Nguyen Hai Nam, Motohiko Sato, Satoru Seo, Keiko Iwaisako, Etsuro Hatano
Background and AimAutotaxin (ATX) is an extracellular lysophospholipase D that catalyzes the hydrolysis of lysophosphatidylcholine into lysophosphatidic acid (LPA). Recent accumulating evidence indicates the biological roles of ATX in malignant tumors. However, the expression and clinical implications of ATX in human cholangiocarcinoma (CCA) remain elusive.MethodsIn this study, the expression of ATX
-
Risk of colorectal cancer in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease compared with primary sclerosing cholangitis only Hepatol. Res. (IF 4.2) Pub Date : 2024-02-29 Taranika Sarkar Das, Kimberly Ho, Jahnavi Udaikumar, Bryan Chen, Olivia Delau, Aasma Shaukat, Ira Jacobson, Raiya Sarwar
-
Impact of electrical muscle stimulation on serum myostatin level and maintenance of skeletal muscle mass in patients undergoing living‐donor liver transplantation: Single‐center controlled trial Hepatol. Res. (IF 4.2) Pub Date : 2024-02-28 Yuriko Tsutsui, Shinji Itoh, Takeo Toshima, Sachiyo Yoshio, Shohei Yoshiya, Takuma Izumi, Norifumi Iseda, Katsuya Toshida, Yuki Nakayama, Takuma Ishikawa, Yukiko Kosai‐Fujimoto, Kazuki Takeishi, Tomoharu Yoshizumi
AimSarcopenia is reportedly associated with a poor prognosis in patients who undergo living‐donor liver transplantation (LDLT), most of whom are not able to tolerate muscle strengthening exercise training. Myostatin is one of the myokines and a negative regulator of skeletal muscle growth. The clinical feasibility of an electrical muscle stimulation (EMS) system, which exercises muscle automatically
-
Noninvasive assessment of portal hypertension based on the Baveno VII criteria Hepatol. Res. (IF 4.2) Pub Date : 2024-02-26 Tadashi Namisaki
CONFLICT OF INTEREST STATEMENT Author declares no Conflict of Interests for this article.
-
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease Hepatol. Res. (IF 4.2) Pub Date : 2024-02-24 Nobuharu Tamaki, Shun‐Ichi Wakabayashi, Takefumi Kimura, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Daniel Q. Huang, Takeji Umemura, Masayuki Kurosaki, Namiki Izumi
-
Correction to “Association of abnormal glucose tolerance with liver‐related disease and cardiovascular diseases in patients with chronic hepatitis C” Hepatol. Res. (IF 4.2) Pub Date : 2024-02-24
Konishi F, Miyake T, Watanabe T, Tokumoto Y, Furukawa S, Matsuura B, et al. Association of abnormal glucose tolerance with liver-related disease and cardiovascular diseases in patients with chronic hepatitis C. Hepatol Res. 2023; 53 (9):806–814. 10.1111/hepr.13925. The Graphical Abstract text, “For diabetes mellitus, neither normal glucose tolerance nor prediabetes, is a significant risk for hepatocellular
-
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2024-02-14 Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, Eisuke Ueshima, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takamichi Murakami, Takumi Fukumoto
-
Diagnostic performance of shear wave measurement in the detection of hepatic fibrosis: A multicenter prospective study Hepatol. Res. (IF 4.2) Pub Date : 2024-02-13 Takashi Kumada, Hidenori Toyoda, Sadanobu Ogawa, Tatsuya Gotoh, Yuichi Yoshida, Masahiro Yamahira, Masashi Hirooka, Yohei Koizumi, Yoichi Hiasa, Tsutomu Tamai, Ryoko Kuromatsu, Toshihisa Matsuzaki, Tomoyuki Suehiro, Yoshihiro Kamada, Yoshio Sumida, Junko Tanaka, Masahito Shimizu
-
Hepatitis B surface antigen glycan isomer is a predictor of the development of hepatocellular carcinoma during nucleoside/nucleotide analog therapy Hepatol. Res. (IF 4.2) Pub Date : 2024-02-07 Ritsuzo Kozuka, Masaru Enomoto, Yoshimi Yukawa-Muto, Naoshi Odagiri, Kohei Kotani, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Hideki Fujii, Sawako Uchida-Kobayashi, Norifumi Kawada
-
Possible pathogenetic role of ammonia in liver cirrhosis without hyperammonemia of venous blood: The so-called latency period of abnormal ammonia metabolism Hepatol. Res. (IF 4.2) Pub Date : 2024-02-07 Kazuhiro Katayama, Naruyasu Kakita
-
Validation of Japanese indication criteria for deceased donor liver transplantation for hepatocellular carcinoma: Analysis of US national registry data Hepatol. Res. (IF 4.2) Pub Date : 2024-02-03 Yuki Bekki, Shinji Itoh, Takeo Toshima, Mototsugu Shimokawa, Tomoharu Yoshizumi
The Japanese indication criteria for liver transplantation (LT) for hepatocellular carcinoma (HCC) have been updated based on living donor LT data to include either the Milan criteria (MC) or the 5-5-500 rule, which requires a nodule size of ≤5 cm, ≤5 nodules, and an alpha-fetoprotein (AFP) level ≤500 ng/mL. We aimed to validate the 5-5-500 rule and the MC for deceased donor LT (DDLT).
-
Impact of the COVID-19 pandemic on the number and short-term outcomes in hepatectomy for hepatocellular carcinoma: Results from the Japanese National Clinical Database, 2018–2021 Hepatol. Res. (IF 4.2) Pub Date : 2024-02-03 Yusuke Takemura, Hideki Endo, Taizo Hibi, Yutaka Nakano, Ryo Seishima, Masashi Takeuchi, Hiroyuki Yamamoto, Hiromichi Maeda, Kazuhiro Hanazaki, Akinobu Taketomi, Yoshihiro Kakeji, Yasuyuki Seto, Hideki Ueno, Masaki Mori, Yuko Kitagawa
-
Issue Information Hepatol. Res. (IF 4.2) Pub Date : 2024-02-02
No abstract is available for this article.
-
Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real-world multicenter cohort study Hepatol. Res. (IF 4.2) Pub Date : 2024-02-01 Hyunjae Shin, Seung Up Kim, Byeong Geun Song, Youngsu Park, Yunmi Ko, Jeayeon Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Dong Hyun Sinn, Yoon Jun Kim
-
Profiles associated with significant hepatic fibrosis consisting of alanine aminotransferase >30 U/L, exercise habits, and metabolic dysfunction-associated steatotic liver disease Hepatol. Res. (IF 4.2) Pub Date : 2024-01-31 Masahito Nakano, Machiko Kawaguchi, Takumi Kawaguchi, Hitoshi Yoshiji
-
A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging-derived proton density fat fraction Hepatol. Res. (IF 4.2) Pub Date : 2024-01-31 Sadanobu Ogawa, Takashi Kumada, Tatsuya Gotoh, Fumihiko Niwa, Hidenori Toyoda, Junko Tanaka, Masahito Shimizu
-
Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO-HBP-005): Clinical Study Group of Osaka University, Hepato-Biliary-Pancreatic Group Hepatol. Res. (IF 4.2) Pub Date : 2024-01-27 Shogo Kobayashi, Akira Tomokuni, Yutaka Takeda, Hiroshi Wada, Yoshiteru Katsura, Kazuhiko Hashimoto, Yoshito Tomimaru, Tadafumi Asaoka, Terumasa Yamada, Masanori Tsujie, Takehiro Noda, Satoshi Morita, Hiroaki Nagano, Masaki Mori, Yuichiro Doki, Hidetoshi Eguchi
-
Attenuation of hepatitis A antibody after immunization with hepatitis A vaccine (Aimmugen) in people living with HIV Hepatol. Res. (IF 4.2) Pub Date : 2024-01-24 Michiko Koga, Makoto Saito, Megumi Kubota, Tomoe Senkoji, Eisuke Adachi, Kazuhiko Ikeuchi, Tadashi Kikuchi, Amato Otani, Kazuaki Takahashi, Takeya Tsutsumi, Hiroshi Yotsuyanagi
Hepatitis A (HA) is a vaccine-preventable disease. In regions with good sanitation, men who have sex with men (MSM) are the key affected populations. During the 2018–2019 HA outbreak among MSM in Japan, we actively vaccinated MSM living with HIV (MSM-LWHIV) with Aimmugen. As previously reported, their antibody seroconversion rate due to vaccination was lower than that of healthy individuals. However
-
Apparent diffusion coefficient in intrahepatic cholangiocarcinoma diffusion-weighted magnetic resonance imaging noninvasively predicts Ki-67 expression Hepatol. Res. (IF 4.2) Pub Date : 2024-01-22 Daiki Hokkoku, Kazuki Sasaki, Shogo Kobayashi, Yoshifumi Iwagami, Daisaku Yamada, Yoshito Tomimaru, Tadafumi Asaoka, Takehiro Noda, Hidenori Takahashi, Junzo Shimizu, Yuichiro Doki, Hidetoshi Eguchi
Tumor Ki-67 expression reflects prognosis and cancer grade, and biopsy-based preoperative assessment of Ki-67 expression is key to treatment. Apparent diffusion coefficient (ADC) values obtained with this imaging may noninvasively predict Ki-67 by reflecting tumor cell density and limited water molecule movement from irregular alignment. This study aimed to investigate the ability of ADC values to
-
Development and validation of a prognostic model for 90-day survival in patients with alcohol-associated cirrhosis and acute decompensation Hepatol. Res. (IF 4.2) Pub Date : 2024-01-19 Hui Quan, Hao Yu, Xiao-Li Liu, Fei-Xiang Xiong, Yi-Xin Hou, Xian-Bo Wang, Zhi-Yun Yang, Yu-Yong Jiang
-
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease Hepatol. Res. (IF 4.2) Pub Date : 2024-01-17 Keito Suzuki, Nobuharu Tamaki, Masayuki Kurosaki, Yuka Takahashi, Yudai Yamazaki, Naoki Uchihara, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Taisei Keitoku, Risa Okada, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi
-
Issue Information Hepatol. Res. (IF 4.2) Pub Date : 2024-01-06
No abstract is available for this article.
-
Impact of metabolic dysfunction-associated fatty liver disease on the incidence of Helicobacter pylori-negative gastric cancer Hepatol. Res. (IF 4.2) Pub Date : 2023-12-29 Tomoyuki Nakane, Shuhei Fukunaga, Dan Nakano, Tsubasa Tsutsumi, Hiroshi Tanaka, Tomonori Chou, Shinpei Minami, Akihiro Ohuchi, Tsutomu Nagata, Kota Takaki, Hiroshi Takaki, Ichiro Miyajima, Ryuichi Nouno, Shinobu Yoshinaga, Michita Mukasa, Yoshinobu Okabe, Takumi Kawaguchi
-
Differential peripheral memory T cell subsets sensitively indicate the severity of nonalcoholic fatty liver disease Hepatol. Res. (IF 4.2) Pub Date : 2023-12-29 Akira Kado, Takeya Tsutsumi, Hiroshi Yotsuyanagi, Kazuhiko Ikeuchi, Kazuya Okushin, Kyoji Moriya, Kazuhiko Koike, Mitsuhiro Fujishiro
-
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study Hepatol. Res. (IF 4.2) Pub Date : 2023-12-28 Jun-Zhe Yi, Zhi-Jian Zhu, Gong-Wei Liu, Yi-Min Zhang, Jie Xu, Xin-Tong Wu, Ke Ding, Jian-Chao Liu, Ke-Fei Zhang, Xiong-Ying Jiang, Qi-Feng Chen, Yue Hu, Song Chen, Sui-Xing Zhong, Jiong-Liang Wang, Ning Lyu, Ming Zhao
-
Advancements in metabolic-associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions Hepatol. Res. (IF 4.2) Pub Date : 2023-12-27 Venkateswararao Eeda, Nikhil Yuvaraj Patil, Aditya Dilip Joshi, Vibhudutta Awasthi
Metabolic (dysfunction)-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is a growing global health concern with no approved pharmacological treatments. At the same time, there are no standard methods to definitively screen for the presence of MASLD because of its progressive nature and symptomatic commonality with other disorders. Recent advances in molecular
-
New concept in fatty liver diseases Hepatol. Res. (IF 4.2) Pub Date : 2023-12-26 Katsutoshi Tokushige
In 2023, the nonalcoholic fatty liver disease (NAFLD) Nomenclature Consensus group proposed a new name and concept for NAFLD/nonalcoholic steatohepatitis. The Japanese Society of Gastroenterology and the Japanese Society of Hepatology have accepted these new names and concepts. It was reported that the terms “nonalcoholic” and “fatty” are misleading and inappropriate, because NAFLD does not reflect
-
An RNA-degrading enzyme emerges as a biomarker in a study of human hepatitis virus B Hepatol. Res. (IF 4.2) Pub Date : 2023-12-26 Takehisa Watanabe, Katsuya Nagaoka
CONFLICT OF INTEREST STATEMENT Authors declare no Conflict of Interests for this article.
-
The change in Fibrosis-4 index in Japanese patients with type 2 diabetes treated by a fixed-ratio combination therapy of insulin degludec and liraglutide: A retrospective observational study Hepatol. Res. (IF 4.2) Pub Date : 2023-12-23 Hiroyuki Ito, Ryota Someya, Shigenori Ando, Rie Araki, Emiko Tsugami, Suzuko Matsumoto, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane
-
Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab Hepatol. Res. (IF 4.2) Pub Date : 2023-12-22 Shun Kaneko, Yasuhiro Asahina, Miyako Murakawa, Shunsuke Ueyama, Chiaki Maeyashiki, Hideki Watanabe, Akiko Kusano-Kitazume, Ayako Sato, Kozue Uchidate, Takehito Asakawa, Sho Watanabe, Yasuhiro Iizuka, Isamu Shibata, Shinya Oooka, Yuko Karakama, Takashi Fujii, Taro Watabe, Keiichi Akahoshi, Minoru Tanabe, Kento Inada, Tomohiro Mochida, Keiya Watakabe, Taro Shimizu, Jun Tsuchiya, Masato Miyoshi, Fukiko
-
Potential role of Fibrosis-4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study Hepatol. Res. (IF 4.2) Pub Date : 2023-12-22 Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min-Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
-
Deciphering the dual nature of the Fibrosis-4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy Hepatol. Res. (IF 4.2) Pub Date : 2023-12-21 Jun Arai, Kiyoaki Ito
CONFLICT OF INTEREST STATEMENT K.I. received research funding from Abbvie and Gilead Sciences.
-
A case of A20 haploinsufficiency complicated by autoimmune hepatitis Hepatol. Res. (IF 4.2) Pub Date : 2023-12-21 Taisei Iwasa, Takao Miwa, Shinji Unome, Tatsunori Hanai, Kenji Imai, Koji Takai, Yuki Miwa, Tomohiro Hori, Hidenori Ohnishi, Munekazu Matsumoto, Ayumi Niwa, Tatsuhiko Miyazaki, Masahito Shimizu
A20 haploinsufficiency (HA20) is a recently described autoinflammatory disease that manifests symptoms similar to those of Behçet's disease. However, little is known about the involvement of the liver in HA20. Here, we report a case of HA20 complicated by autoimmune hepatitis (AIH).
-
A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report Hepatol. Res. (IF 4.2) Pub Date : 2023-12-19 Yusuke Kawamura, Norio Akuta, Shunichiro Fujiyama, Tetsuya Hosaka, Satoshi Saitoh, Hitomi Sezaki, Fumitaka Suzuki, Yoshiyuki Suzuki, Kenji Ikeda, Yasuji Arase, Hiromitsu Kumada
-
Cost-effectiveness of hepatitis E virus vaccination strategy Hepatol. Res. (IF 4.2) Pub Date : 2023-12-13 Hideaki Kato
CONFLICT OF INTEREST STATEMENT Author declares no conflict of interests for this article.
-
Issue Information Hepatol. Res. (IF 4.2) Pub Date : 2023-12-02
No abstract is available for this article.
-
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2023-11-29 Yoko Yoshimaru, Katsuya Nagaoka, Kentaro Tanaka, Satoshi Narahara, Hiroki Inada, Sotaro Kurano, Takayuki Tokunaga, Etsuko Iio, Takehisa Watanabe, Hiroko Setoyama, Masakuni Tateyama, Koji Yoshida, Takuya Tsunoda, Yusuke Nakamura, Motohiko Tanaka, Yutaka Sasaki, Yasuhito Tanaka
We evaluated the safety and efficacy of vascular endothelial growth factor receptor (VEGFR)-targeted peptide vaccines for the immunization of patients with unresectable hepatocellular carcinoma (HCC) who had responded to transarterial chemoembolization.
-
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis Hepatol. Res. (IF 4.2) Pub Date : 2023-11-28 Natsuko Kobayashi, Toshifumi Tada, Takashi Nishimura, Tomomitsu Matono, Yukihisa Yuri, Tomoyuki Takashima, Nobuhiro Aizawa, Naoto Ikeda, Shinya Fukunishi, Mariko Hashimoto, Mitsumasa Ohyanagi, Hirayuki Enomoto, Hiroko Iijima
It remains unclear whether the newly defined concept of metabolic dysfunction-associated steatotic liver disease (MASLD) appropriately includes patients with nonalcoholic fatty liver disease with significant liver fibrosis.
-
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study Hepatol. Res. (IF 4.2) Pub Date : 2023-11-20 Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi
-
Cost-effectiveness analysis of adult living-donor liver transplantation in Japan Hepatol. Res. (IF 4.2) Pub Date : 2023-11-20 Tetsuya Tajima, Jung-Ho Shin, Susumu Kunisawa, Noriko Sasaki, Koichiro Hata, Kiyohide Fushimi, Etsuro Hatano, Yuichi Imanaka
-
The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study Hepatol. Res. (IF 4.2) Pub Date : 2023-11-20 Kazuhiro Murai, Hayato Hikita, Takahiro Kodama, Masaki Kaibori, Yuki Nishimura, Tomohide Tatsumi, Tomomi Yamada, Tatsuya Kanto, Satoshi Mochida, Tetsuo Takehara
-
Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study Hepatol. Res. (IF 4.2) Pub Date : 2023-11-17 Tomoya Sano, Keisuke Amano, Tatsuya Ide, Hiroshi Isoda, Yuichi Honma, Yasuyo Morita, Yoichi Yano, Hiroki Nakamura, Satoshi Itano, Ichiro Miyajima, Miki Shirachi, Reiichiro Kuwahara, Miki Ohno, Toshihiro Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Teruko Arinaga-Hino, Machiko Kawaguchi, Yuichiro Eguchi, Takuji Torimura, Hirokazu Takahashi, Masaru Harada, Takumi Kawaguchi
-
Correction to Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2023-11-13
Doi Y, Nagata Y, Matsumoto Y, Numata K, Sasaki R, Yamada T, et al. Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma. Hepatol Res. 2023; 53 (8):749–760. In the Results section of the Abstract, the text “The 3-year overall survival, recurrence-free survival, and cumulative incidence of local recurrence rates
-
Galectin-3 in biliary atresia and other pediatric cholestatic liver diseases Hepatol. Res. (IF 4.2) Pub Date : 2023-11-11 Dor Yoeli, Cara L. Mack, Yuhuan Luo, Alexander Chaidez, Nathaly Limon De La Rosa, Zhaohui Wang, Eduardo Cervantes-Alvarez, Christene A. Huang, Nalu Navarro-Alvarez
-
Potential involvement of oncostatin M in the immunosuppressive tumor immune microenvironment in hepatocellular carcinoma with vessels encapsulating tumor clusters Hepatol. Res. (IF 4.2) Pub Date : 2023-11-10 Yasuyuki Shigematsu, Kazuhito Tanaka, Gulanbar Amori, Hiroaki Kanda, Yu Takahashi, Yutaka Takazawa, Kengo Takeuchi, Kentaro Inamura
-
Effects of weight loss on metabolic dysfunction-associated fatty liver disease in Japanese people: Non-alcoholic fatty liver disease in the Gifu area, longitudinal analysis study Hepatol. Res. (IF 4.2) Pub Date : 2023-11-08 Yuka Hasegawa, Hiroshi Okada, Hanako Nakajima, Nobuko Kitagawa, Takuro Okamura, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Yuki Nakahata, Akihiro Obora, Takao Kojima, Masahide Hamaguchi, Michiaki Fukui
-
Impact of post-progression survival in second-line treatment with molecular target agents for unresectable hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2023-11-04 Kazuto Tajiri, Nozomu Muraishi, Aiko Murayama, Yuka Hayashi, Ichiro Yasuda
Sequential therapies are essential to extend overall survival (OS) in patients with unresectable hepatocellular carcinoma (HCC). Several second-line treatments with molecular target agents have shown survival benefits. However, the significance of post-progression survival (PPS) in extending OS in patients with HCC given such treatments remains uncertain.
-
Liver abscess after drug-eluting bead transarterial chemoembolization for hepatic malignant tumors: Clinical features, pathogenesis, and management Hepatol. Res. (IF 4.2) Pub Date : 2023-11-04 Li-Jun Wang, Liang Yin, Kai-Cai Liu, Wei-Fu Lv, Dong Lu
The study aimed to investigate the clinical features, incidence, pathogenesis, and management of liver abscess after drug-eluting bead transarterial chemoembolization (DEB-TACE) for primary and metastatic hepatic malignant tumors.
-
Issue Information Hepatol. Res. (IF 4.2) Pub Date : 2023-11-02
No abstract is available for this article.
-
Hepatic steatosis and skeletal muscle alterations during the COVID-19 lockdown in a cohort of patients with chronic liver disease in Japan Hepatol. Res. (IF 4.2) Pub Date : 2023-11-03 Akira Uchiyama, Kazuyoshi Kon, Satoshi Sakuma, Toshifumi Sato, Maki Morinaga, Hiroo Fukada, Hisafumi Yamagata, Reiko Yaginuma, Kyoko Fukuhara, Shunhei Yamashina, Shuko Nojiri, Kenichi Ikejima
-
DNA methylation alterations of ADCY5, MICAL2, and PLEKHG2 during the developmental stage of cryptogenic hepatocellular carcinoma Hepatol. Res. (IF 4.2) Pub Date : 2023-10-31 Satomi Makiuchi, Ying Tian, Mao Fujimoto, Junko Kuramoto, Noboru Tsuda, Hidenori Ojima, Masahiro Gotoh, Nobuyoshi Hiraoka, Teruhiko Yoshida, Yae Kanai, Eri Arai
-
Recent advances in hepatitis A virus research and clinical practice guidelines for hepatitis A virus infection in Japan Hepatol. Res. (IF 4.2) Pub Date : 2023-10-31 Tatsuo Kanda, Reina Sasaki-Tanaka, Koji Ishii, Ryosuke Suzuki, Jun Inoue, Atsunori Tsuchiya, Shingo Nakamoto, Ryuzo Abe, Keiichi Fujiwara, Osamu Yokosuka, Tian-Cheng Li, Satoshi Kunita, Hiroshi Yotsuyanagi, Hiroaki Okamoto
-
Effects of entecavir and tenofovir alafenamide fumarate treatment on renal function in Japanese elderly patients with chronic hepatitis B Hepatol. Res. (IF 4.2) Pub Date : 2023-10-28 Misako Tanaka, Takemi Akahane, Hideto Kawaratani, Nobuyuki Yorioka, Aritoshi Koizumi, Shohei Asada, Takuya Matsuda, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, Koh Kitagawa, Kosuke Kaji, Tadashi Namisaki, Hitoshi Yoshiji
-
Causal association of nonalcoholic fatty liver disease with 22 extrahepatic cancers: A Mendelian randomization study Hepatol. Res. (IF 4.2) Pub Date : 2023-10-25 Jiarong Xie, Hui Gao, Cenqin Liu, Yue Pan, Chengfu Xu, Lei Xu
It is unclear whether nonalcoholic fatty liver disease (NAFLD) acts as a direct contributing factor to multiple extrahepatic cancers. We aimed to systematically investigate the causal relationships of NAFLD with extrahepatic cancers.
-
Serum RNase L levels in patients with chronic hepatitis B virus infection Hepatol. Res. (IF 4.2) Pub Date : 2023-10-20 Chi-Ling Chen, Tai-Chung Tseng, Chun-Jen Liu, Jia-Horng Kao, Pei-Jer Chen, Wei-Shiung Yang
Chronic hepatitis B virus (HBV) infection still poses a major threat to global health. Oligoadenylate synthetase–ribonuclease L (RNase L) antiviral pathway is one of interferon-induced antiviral effectors. The relationship between RNase L and HBV has never been investigated and we aim to examine the serum RNase L levels in patients with different stages of chronic HBV infection.
-
Noninvasive graft monitoring using donor-derived cell-free DNA in Japanese liver transplantation Hepatol. Res. (IF 4.2) Pub Date : 2023-10-18 Hiroki Kanamori, Yohei Yamada, Yoko Ito, Koji Shirosaki, Satoko Yamagishi, Yutaro Maeda, Yumi Kudo, Tomoshige Umeyama, Nobuhiro Takahashi, Mototoshi Kato, Yasushi Hasegawa, Kentaro Matsubara, Masahiro Shinoda, Hideaki Obara, Rie Irie, Hanako Tsujikawa, Hajime Okita, Phuong Thanh Nguyen, Kenichi Saigo, Shigeki Mitsunaga, Ituro Inoue, Yuko Kitagawa, Tatsuo Kuroda